Not every business in operation today is built to thrive -- or even last -- indefinitely. These are.The overall market shows clear indications that it's priced at relatively rich levels right now. But smart investors willing to do a little digging will find that there are always at least a few undervalued stocks worth consideration.The real difficulty though is finding undervalued names you want to buy and hold forever. These companies must be in true "forever" businesses. And, these companies must also be ...

Planning Underway for Phase 3 Development of Tezepelumab in COPD  THOUSAND OAKS, Calif., April 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT. We are encouraged by the resul ...

Due to its obvious nature, one of the most commonly repeated pieces of advice regarding stock investment is to buy undervalued stocks when they trade low and sell overvalued stocks when they trade high. Achieving this outcome consistently would be ideal. However, the challenge lies not only in identifying overvalued and undervalued stocks trading at appreciated or depressed prices but also in those with promising potential.There may be several reasons why undervalued stocks do not reflect their intrinsic va ...

Vertigo3d Anybody who's invested in the pharmaceutical space knows that industry giants like Pfizer (PFE) and Gilead Sciences (GILD) are subject to boom and bust cycles as it relates to patent cliffs and new drug development. That's why capital allocation is so important to sustaining shareholder returns, and those who can do it well tend to outperform peers and even the market itself. This brings me to Amgen (NASDAQ:AMGN), which has done well for shareholders over its history. I last covered the stock back ...

JHVEPhoto "Science Lessons" is a famous book by Gordon Binder, the now 89 year-old who led Amgen (NASDAQ:AMGN) as CEO from 1988-2000 and CFO from 1982-1988. It discusses Amgen's growth as a biopharmaceutical company, along with the company's core focuses on discovery and science in what is an incredibly tough industry. As we'll see throughout this article, despite Amgen's recent stock price stagnation, the company has one of the best portfolios in the industry, making it a valuable investment. Amgen Horizon ...

Amgen (AMGN) ended the recent trading session at $270, demonstrating a +1.33% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.74%. Meanwhile, the Dow experienced a drop of 0.01%, and the technology-dominated Nasdaq saw an increase of 1.68%.Shares of the world's largest biotech drugmaker have depreciated by 3.46% over the course of the past month, outperforming the Medical sector's loss of 4.72% and lagging the S&P 500's gain of 0.8%.The upcoming e ...

These drugmakers have made important moves over the past year.The biotech industry can be attractive for several reasons. Many leading biotechs develop innovative, life-saving therapies, a business that will only be phased out once we find an all-purpose cure for all illnesses. Further, biotechs often deliver better-than-average financial results during economic downturns because the products they sell are considered necessary goods.Of course, not every biotech company is worth investing in. Let's consider ...

PM Images/DigitalVision via Getty Images Introduction Over the past few years, I have increasingly focused on one major issue: the looming retirement crisis. Although every time I use the word "crisis" in a title, I feel guilty of clickbait, there's no denying that it's an appropriate use of the word, as we're increasingly moving to a situation that could see significant retirement funding shortages. The Guardian headline below is a good example of this: The Guardian My most recent article on this subje ...

Amgen (AMGN) is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health, nephrology and neuroscience markets.Thousand Oaks, CA-based Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. Biosimilar drugs are also a key part of Amgen’s growth strategy. ...

Key PointsThe iShares Biotechnology ETF (IBB) is consolidating in the upper range, suggesting a potential sector breakout.Despite modest YTD gains in the biotech sector, the recent consolidation has contracted further, hinting at energy buildup for a higher breakout.The sector ETF's key holdings are Amgen (AMGN), Vertex Pharmaceuticals (VRTX), and Gilead Sciences (GILD), which influence sector direction and momentum.5 stocks we like better than Gilead SciencesThe popular iShares Biotechnology ETF NASDAQ: IB ...